NCT04613492View on ClinicalTrials.gov

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Solid Tumors
Interventions
BIOLOGICAL

MEDI9253

Participants will receive either single or multiple dose of MEDI9253; sequentially or concurrent with Durvalumab

BIOLOGICAL

Durvalumab

Participants will receive durvalumab treatment sequentially or concurrently with MEDI9253

Trial Locations (8)

10032

Research Site, New York

10065

Research Site, New York

14263

Research Site, Buffalo

15232

Research Site, Pittsburgh

31100

Research Site, Toulouse

33076

Research Site, Bordeaux

63110

Research Site, St Louis

94800

Research Site, Villejuif

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY